Gregory Russotti
Net worth: 1 M $ as of 2026-05-30
Net worth: 1 M $ as of 2026-05-30
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. since 2023.
Formerly, Dr. Russotti was VP, Cell Therapy Development and Operations at Celgene Corp.
from 2013 to 2019.
Education includes a doctorate from Rutgers State University of New Jersey conferred in 1996, and undergraduate and graduate degrees from Rensselaer Polytechnic Institute conferred in 1988 and 1990, respectively.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-11 | 605,092 ( 0.34% ) | 1 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-12-31 |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Consultant / Advisor | - |
| Companies | Position | End |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 2019-12-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Finance |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions